The purpose of this study was to investigate the use of hepatocyte gro
wth factor as a biochemical marker for acute myocardial infarction. Se
veral biochemical markers are used for noninvasive detection of acute
myocardial infarction, However, hepatocyte growth factor has not been
used previously for this purpose. We measured hepatocyte growth factor
, creatine phosphokinase, and MB isoenzyme (CK-MB) levels in 6 patient
s with stable effort angina after diagnostic catheterization (controls
) and in 12 patients with acute myocardial infarction (AMI). The measu
rements in the AMI patients were recorded twice a day for the first 3
days after onset of chest pain and once a day for the next 4 days. Fur
thermore, in each patient we evaluated the time to reach the maximum l
evel and the time for the level to decline to less than half the maxim
um. Hepatocyte growth factor levels (ng/ml) were 0.3 +/- 0.1 for angin
a pectoris patients, and 15.7 +/- 9.1 within 6 h and 12.5 +/- 4.6 with
in 12 h after the onset for AMI patients, respectively. The correlatio
n coefficients between hepatocyte growth factor and creatine phosphoki
nase and between hepatocyte growth factor and CK-MB were 0.68 and 0.74
, respectively. The time to reach the maximum (h) and the time to decl
ine to less than half of the maximum level (days) were 6.6 +/- 2.6 and
1.2 +/- 0.2 for hepatocyte growth factor, 19.4 +/- 8.7 and 2.5 +/- 1.
4 for creatine phosphokinase, and 16.6 +/- 7.7 and 1.5 +/- 0.4 for CK-
MB, respectively. Hepatocyte growth factor is useful as a prognostic i
ndicator and reflects the clinical course in patients with acute myoca
rdial infarction.